title: Hypertonic saline reduces inflammation and enhances the resolution of oleic acid induced acute lung injury.
abstract: BACKGROUND
  Hypertonic saline (HTS) reduces the severity of lung injury in ischemia-reperfusion, endotoxin-induced and ventilation-induced lung injury. However, the potential for HTS to modulate the resolution of lung injury is not known. We investigated the potential for hypertonic saline to modulate the evolution and resolution of oleic acid induced lung injury.
  
  
  METHODS
  Adult male Sprague Dawley rats were used in all experiments. Series 1 examined the potential for HTS to reduce the severity of evolving oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 12) or hypertonic saline (HTS, n = 12), and the extent of lung injury assessed after 6 hours. Series 2 examined the potential for HTS to enhance the resolution of oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 6) or hypertonic saline (HTS, n = 6), and the extent of lung injury assessed after 6 hours.
  
  
  RESULTS
  In Series I, HTS significantly reduced bronchoalveolar lavage (BAL) neutrophil count compared to Control [61.5 +/- 9.08 versus 102.6 +/- 11.89 x 10(3) cells.ml-1]. However, there were no between group differences with regard to: A-a O2 gradient [11.9 +/- 0.5 vs. 12.0 +/- 0.5 KPa]; arterial PO2; static lung compliance, or histologic injury. In contrast, in Series 2, hypertonic saline significantly reduced histologic injury and reduced BAL neutrophil count [24.5 +/- 5.9 versus 46.8 +/- 4.4 x 10(3) cells.ml-1], and interleukin-6 levels [681.9 +/- 190.4 versus 1365.7 +/- 246.8 pg.ml-1].
  
  
  CONCLUSIONS
  These findings demonstrate, for the first time, the potential for HTS to reduce pulmonary inflammation and enhance the resolution of oleic acid induced lung injury.
authors.affiliation: Lung Biology Group, National Centre for Biomedical Engineering Sciences, National University of Ireland, Galway, Ireland. muiris_kennedy@yahoo.ie
authors.forename: Muiris T
authors.initials: MT
authors.lastname: Kennedy
authors.forename: Brendan D
authors.initials: BD
authors.lastname: Higgins
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Costello
authors.forename: William A
authors.initials: WA
authors.lastname: Curtin
authors.forename: John G
authors.initials: JG
authors.lastname: Laffey
mesh_terms: D000208:Acute Disease; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015850:Interleukin-6 / Q000097:blood; D007958:Leukocyte Count; D008171:Lung Diseases / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009504:Neutrophils / Q000473:pathology; D019301:Oleic Acid; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use*
chemical_list: D015850:Interleukin-6; D012462:Saline Solution, Hypertonic; D019301:Oleic Acid